Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Founded in 2018, the company's mission is to transform treatment paradigms by creating scalable, affordable, and off-the-shelf cell therapies.

The company's core technology involves engineering induced pluripotent stem cells (iPSCs) and differentiating them into induced mesenchymal stem cells (iMSCs). These allogeneic synthetic iMSCs are designed to provide a scalable, off-the-shelf treatment solution, eliminating the need for patient-specific cell harvesting. Ernexa's pipeline includes ERNA-101, a lead cell therapy product aimed at activating the immune system to combat cancer cells, with an initial focus on platinum-resistant ovarian cancer. Additionally, ERNA-201 is being developed to target inflammation and treat autoimmune diseases such as rheumatoid arthritis.

Sanjeev Luther serves as the President and CEO of Ernexa Therapeutics. The company, which was formerly known as Eterna Therapeutics Inc. and underwent a name change in March 2025 to reflect its sharpened strategic focus, is publicly traded on Nasdaq under the ticker symbol ERNA. In April 2026, Ernexa Therapeutics announced a 1-for-25 reverse stock split, effective May 4, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company is advancing towards first-in-human clinical trials in 2026, following a successful Pre-IND meeting with the U.S. FDA for ERNA-101 in ovarian cancer.

Latest updates

Ernexa Therapeutics Executes 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing

Event summary

  • Ernexa Therapeutics (ERNA) announced a 1-for-25 reverse stock split, effective May 4, 2026.
  • The split is intended to regain compliance with the Nasdaq $1.00 minimum bid price requirement.
  • Shareholders approved the split by written consent on March 27, 2026, with a voting power of approximately 53.34%.
  • The split will reduce the number of outstanding shares from approximately 29.16 million to roughly 1.17 million.
  • The CUSIP number for the Common Stock following the reverse stock split will be 114082407.

The big picture

Ernexa's reverse stock split is a common, albeit often unwelcome, maneuver for companies facing delisting risk. While the company emphasizes its strategic priorities and pipeline advancements, the split highlights underlying financial pressures and the need to maintain access to capital markets. The move signals a need to bolster investor confidence and potentially attract a different class of investor focused on longer-term value rather than short-term speculation.

What we're watching

Listing Stability
Whether the reverse split will sustainably restore the share price above the Nasdaq minimum, or if further corrective actions will be required.
Investor Sentiment
How the market perceives the reverse split, as it can be viewed negatively by some investors and potentially impact future fundraising efforts.
Pipeline Progress
The pace at which Ernexa advances its clinical programs (ERNA-101 and ERNA-102) will be critical to justifying the current valuation and maintaining investor confidence.
CID: 3190